Advertisement
Advertisement
IGC
IGC Pharma, Inc.
0.26
USDSponsored
+0.01
+4.35%
Mar 25, 15:12 UTC -4
Closed
Pre-Market
0.26
0.00
-0.38%
IGC Earnings Reports
Positive Surprise Ratio
IGC beat 4 of 6 last estimates.
67%
Next Report
Date of Next Report
Jun 25, 2026
Estimate for Q4 26 (Revenue/ EPS)
$264.12K
/-$0.02
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
-19.97%
/+100.00%
IGC Pharma, Inc. earnings per share and revenue
On Mar 02, 2026, IGC reported earnings of -- USD per share (EPS) for Q3 26, -- the estimate of -0.02 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 261.59 thousand, with a --% difference.
Looking ahead to Q4 26, 2 analysts forecast an EPS of -0.02 USD, with revenue projected to reach 264.12 thousand USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Talphera, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
Theravance Biopharma, Inc.
Report Date
Mar 19, 2026 For Q4 25
Estimate
$1.24
Actual
$0.21
Surprise
-83.12%
Relmada Therapeutics, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.14
Actual
-$0.28
Surprise
-103.08%
Context Therapeutics Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.14
Surprise
-29.39%
Avalo Therapeutics, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$1.49
Actual
-$1.12
Surprise
+24.33%
Journey Medical Corporation Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.04
Surprise
+31.86%
Surrozen, Inc. Common
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$1.21
Actual
-Surprise
-
Achieve Life Sciences, Inc.
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.12%
Pyxis Oncology, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.34
Actual
-$0.28
Surprise
+15.55%
Fractyl Health, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
$0.15
Surprise
+181.70%
FAQ
What were IGC Pharma, Inc.'s earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, IGC Pharma, Inc. reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to IGC Pharma, Inc.'s Q3 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is IGC Pharma, Inc. expected to report next?
The next earning report is scheduled for Jun 25, 2026.
What are the forecasts for IGC Pharma, Inc.'s next earnings report?
Based on 2
analysts, IGC Pharma, Inc. is expected to report EPS of -$0.02 and revenue of $264.12K for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement